4 Stocks Improving Performance Of The Drugs Industry

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 119 points (0.7%) at 16,493 as of Wednesday, Jan. 15, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,941 issues advancing vs. 990 declining with 158 unchanged.

The Drugs industry currently sits up 0.6% versus the S&P 500, which is up 0.5%. Top gainers within the industry include Intercept Pharmaceuticals ( ICPT), up 2.7%, Pfizer ( PFE), up 0.7% and Amgen ( AMGN), up 0.6%. On the negative front, top decliners within the industry include Alnylam Pharmaceuticals ( ALNY), down 5.6%, Isis Pharmaceuticals ( ISIS), down 3.8%, Incyte ( INCY), down 3.6%, Forest Laboratories ( FRX), down 1.0% and Biogen Idec ( BIIB), down 0.8%.

TheStreet would like to highlight 4 stocks pushing the industry higher today:

4. AstraZeneca ( AZN) is one of the companies pushing the Drugs industry higher today. As of noon trading, AstraZeneca is up $0.74 (1.2%) to $62.91 on average volume. Thus far, 1.0 million shares of AstraZeneca exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $62.49-$62.97 after having opened the day at $62.58 as compared to the previous trading day's close of $62.17.

AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for cardiovascular, gastrointestinal, neuroscience, infection, oncology, and respiratory and inflammation diseases worldwide. AstraZeneca has a market cap of $75.0 billion and is part of the health care sector. The company has a P/E ratio of 11.9, below the S&P 500 P/E ratio of 17.7. Shares are up 4.7% year-to-date as of the close of trading on Tuesday. Currently there is 1 analyst who rates AstraZeneca a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates AstraZeneca as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full AstraZeneca Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, GlaxoSmithKline ( GSK) is up $0.51 (1.0%) to $53.08 on average volume. Thus far, 1.8 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 2.4 million shares. The stock has ranged in price between $52.90-$53.14 after having opened the day at $52.97 as compared to the previous trading day's close of $52.57.

GlaxoSmithKline plc, together with its subsidiaries, discovers, develops, manufactures, and markets pharmaceutical products, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $125.9 billion and is part of the health care sector. The company has a P/E ratio of 15.6, below the S&P 500 P/E ratio of 17.7. Shares are down 1.5% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate GlaxoSmithKline a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates GlaxoSmithKline as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, good cash flow from operations, increase in stock price during the past year, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full GlaxoSmithKline Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Allergan ( AGN) is up $1.93 (1.6%) to $123.15 on average volume. Thus far, 1.2 million shares of Allergan exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $120.95-$123.15 after having opened the day at $121.00 as compared to the previous trading day's close of $121.22.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $34.0 billion and is part of the health care sector. The company has a P/E ratio of 27.1, above the S&P 500 P/E ratio of 17.7. Shares are up 9.1% year-to-date as of the close of trading on Tuesday. Currently there are 10 analysts who rate Allergan a buy, no analysts rate it a sell, and 9 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Eli Lilly and Company ( LLY) is up $0.70 (1.3%) to $53.14 on average volume. Thus far, 2.6 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.8 million shares. The stock has ranged in price between $52.42-$53.30 after having opened the day at $52.59 as compared to the previous trading day's close of $52.44.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $58.7 billion and is part of the health care sector. The company has a P/E ratio of 11.9, below the S&P 500 P/E ratio of 17.7. Shares are up 2.8% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts who rate Eli Lilly and Company a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, attractive valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Dow Trades Lower as Apple's Slump Offsets Gains in General Electric

Dow Trades Lower as Apple's Slump Offsets Gains in General Electric

Could Spotify Be Next on Amazon's Wish List?

Could Spotify Be Next on Amazon's Wish List?

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Sprint, T-Mobile Might Have to Do More Than Make Promises to Get Deal Approved

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Skechers Slumps the Most in Two Years After Soft Guidance Overshadows Solid Q1

Video: This Is One Way Millennials Are Destroying Their Financial Future

Video: This Is One Way Millennials Are Destroying Their Financial Future